Bristol renews Ixsys collaboration with up to $40 mil. for research in solid tumor antigen drug targets.
BRISTOL-MYERS SQUIBB RENEWS IXSYS AGREEMENT WITH $40 MIL. INVESTMENT over three years for research to identify solid tumor-related antigens for therapeutic targets, the companies announced Oct. 16. Under the new agreement, BMS will provide $18 mil. up front in equity and research funding. Future milestone payments could bring the total to $40 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth